COMPARISON OF THE CARDIOTOXICITY OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING REAL-WORLD DATA

被引：0
|
作者：
Hu, Jason
Aprikian, Armen
Vanhuyse, Marie
Dragomir, Alice
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP24-18
引用
收藏
页码：E418 / E419
页数：2
相关论文
共 50 条
  • [1] Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.
    Hu, Jason
    Aprikian, Armen G.
    Vanhuyse, Marie
    Dragomir, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
    Raju, R.
    Sahu, A.
    Klevansky, M.
    Torres, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1332 - S1332
  • [3] REAL-WORLD DATA ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE IN REGIONAL ONCOLOGY SERVICE
    Lie, Gabrielle
    Wong, Zee Wan
    Saqib, Ayesha
    Tamjid, Babak
    Torres, Javier
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 51 - 51
  • [4] Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
    Ayşe Demirci
    Cemil Bilir
    Burcu Gülbağcı
    İlhan Hacıbekiroğlu
    İbrahim V. Bayoğlu
    İrem Bilgetekin
    Sinan Koca
    Havva Y. Çınkır
    Nadiye Akdeniz
    Deniz Gül
    Ceyhun Varım
    Umut Demirci
    Berna Öksüzoğlu
    Scientific Reports, 11
  • [5] Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
    Demirci, Ayse
    Bilir, Cemil
    Gulbagci, Burcu
    Hacibekiroglu, Ilhan
    Bayoglu, Ibrahim, V
    Bilgetekin, Irem
    Koca, Sinan
    Cinkir, Havva Y.
    Akdeniz, Nadiye
    Gul, Deniz
    Varim, Ceyhun
    Demirci, Umut
    Oksuzoglu, Berna
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study
    Shore, Neal D.
    Ionescu-Ittu, Raluca
    Laliberte, Francois
    Yang, Lingfeng
    Lejeune, Dominique
    Yu, Louise
    Duh, Mei Sheng
    Mahendran, Malena
    Kim, Jeri
    Ghate, Sameer R.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 480 - 490
  • [7] Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).
    Lopez-Campos, Fernando
    Lorente, David
    Llacer Perez, Casilda
    Ramirez-Backhaus, Miguel
    Peleteiro, Paula
    Gomez-Iturriaga, Alfonso
    Henriquez-Lopez, Ivan
    Lozano, Rebeca
    Romero, Nuria
    Alonso-Gordoa, Teresa
    Molina-Cerrillo, Javier
    Navarro-Castellon, Joaquin
    Castano, Ana
    Pelari, Lira
    Hernandez-Corrales, Antonio
    Morillo, Virginia
    Garcia, Raquel
    Ferrer Albiach, Carlos
    Castro, Elena
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Real-world treatment patterns in French metastatic castration-resistant prostate cancer patients under abiraterone or enzalutamide
    Scailteux, L. M.
    Vincendeau, S.
    Gravis, G.
    Mathieu, R.
    Balusson, F.
    Kerbrat, S.
    Oger, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 10 - 11
  • [9] Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis
    Oyman, Abdilkerim
    Basak, Mustafa
    Ozcelik, Melike
    Ozyukseler, Deniz Tataroglu
    Isik, Selver
    Yildirim, Mahmut Emre
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E201 - E207
  • [10] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
12345